文献速递核素与放射性配体治疗骨显像与常规 SPECT放射性药物与辐射防护

广泛骨转移去势抵抗性前列腺癌患者[225Ac]Ac-PSMA-617 α-放射性配体治疗的血液学毒性特征与疗效

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-04-06

该回顾性研究纳入106例广泛骨转移的去势抵抗性前列腺癌患者,评估[225Ac]Ac-PSMA-617治疗的血液学毒性与疗效。98例(92.5%)基线血液学参数异常,3级贫血、白细胞减少和血小板减少分别见于1例(0.9%)、3例(2.8%)和2例(1.9%),1例发生4级血小板减少。年龄、治疗周期数和肾功能不全是血液学毒性的显著预测因素。

要点

  • 广泛骨转移mCRPC患者中,[225Ac]Ac-PSMA-617的3级及以上血液学毒性发生率低。
  • 年龄、治疗周期数和肾功能不全是血液学毒性的显著预测因素。

核心结论

  • [225Ac]Ac-PSMA-617对约80%的广泛骨转移mCRPC患者产生良好的抗肿瘤效果,且严重血液学毒性发生率低。
  • 年龄、治疗周期数和肾功能不全是[225Ac]Ac-PSMA-617治疗血液学毒性的显著危险因素。

研究设计与样本

  • 回顾性研究,纳入106例接受[225Ac]Ac-PSMA-617治疗的mCRPC患者,基线[68Ga]Ga-PSMA-11 PET/CT显示超级骨显像模式或20个及以上多灶性骨转移灶。

主要发现

  • 34例(32.1%)为超级骨显像模式,72例(67.9%)为多灶性骨转移;中位治疗周期为4(范围1-9)。
  • 98例(92.5%)基线血液学参数异常;3级贫血1例(0.9%)、3级白细胞减少3例(2.8%)、3级血小板减少2例(1.9%),4级血小板减少1例。
  • 年龄、治疗周期数和肾功能不全是血液学毒性的显著预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. We aimed to investigate the hematologic toxicity and efficacy of [225Ac]Ac-PSMA-617 therapy in patients with extensive skeletal metastases of mCRPC. METHODS: We retrospectively reviewed the medical record of patients treated with [225Ac]Ac-PSMA-617 for mCRPC. We included patients with a superscan pattern of skeletal metastases and those with 20 or more multifocal sites of skeletal metastases on baseline [68 Ga]Ga-PSMA-11 PET/CT. We reviewed the levels of hemoglobin, white blood cell (WBC), and platelet prior to each cycle of treatment and determined the presence of impaired bone marrow function at baseline and the grade of toxicity in the hematologic parameters induced by treatment. We evaluated the predictors of hematologic toxicity using binary logistic regression analysis. We also determined the presence of renal dysfunction before or during treatment. We assessed response to treatment using prostate-specific antigen response and the progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 106 patients were included. Skeletal metastasis was in the superscan pattern in 34 patients (32.1%) and multifocal in 72 patients (67.9%). The median treatment cycle was 4 (range = 1-9). Ninety-eight patients (92.5%) had abnormal baseline hematologic parameters. One patient had grade 4 thrombocytopenia. Grade 3 anemia, leukopenia, and thrombocytopenia were seen in 1 (0.9%), 3 (2.8%), and 2 (1.9%) patients, respectively. Age, the number of treatment cycles, and the presence of renal dysfunction were significant predictors of hematologic toxicity. Eighty-five patients (80.2%) achieved PSA response. The median PFS and OS of the study population were 14:00 (95%CI: 8.15-19.86) months and 15.0 (95%CI: 12.8-17.2) months, respectively. CONCLUSIONS: [225Ac]Ac-PSMA-617 induces a good anti-tumor effect in about 80% of patients with extensive skeletal metastases of mCRPC with a rare incidence of severe hematologic toxicity. Age, number of treatment cycles, and the presence of renal dysfunction were significant risk factors for hematologic toxicity of [225Ac]Ac-PSMA-617 therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lawal IO, Morgenstern A, Vorster M, et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35384462. doi:10.1007/s00259-022-05778-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。